Pharmaceutical

Pharma sector needs a supportive environment

Kaisha Pharma will manufacture ampoules, vials, prefilled syringes and cartridges, while targeting Indian and global pharmaceutical and biotechnology companies

Rubicon's share price hit a new high of ₹1,800 soaring 11 per cent on the BSE in Monday's intra-day deals amid heavy volume after reporting healthy earnings for Q1FY27.

GSK India aims to double revenue to ₹8,000 crore by FY30, with oncology and adult vaccines emerging as key growth drivers alongside its general-medicines portfolio

No deadline set for policy; non-scheduled drugs account for 82% of market, average channel markup on common dosage forms is 43%

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

USFDA has granted final approval to Zydus Lifesciences' generic version of IC-Green, an imaging agent used in vascular, transplant and cancer surgeries.

Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside

In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.

Profit before tax rose 42.4 per cent to ₹769 crore as expenses grew slower than revenue and finance costs declined 35.6 per cent; tax expense more than doubled

The Swedish beauty brand will retain its commercial operations in India while entering a long-term manufacturing and supply partnership with Akums

Cadila Pharmaceuticals said Aciloc 150+ and Aciloc 300+ remain available without any restrictions on manufacture or sale, while reaffirming compliance with regulatory requirements

Restructuring positions biotech arm to focus on biologics and biosimilar

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

The exemption, announced earlier this year, covers 40 petrochemical products used for making plastics and pharmaceuticals and is currently valid through June 30

In the past two months, the stock price of Panacea Biotec has skyrocketed 101 per cent.